Physician profile
Lisa Peng
NPI 1235206897
$1,009.29
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $118 · 2021: $142 · 2022: $171 · 2023: $75.43 · 2024: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $182.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $466.82 | 2019-2024 | Mounjaro |
| Pfizer INC. | $107.12 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $87.42 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.48 | 2019-2022 | |
| Gilead Sciences, INC. | $49.14 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.67 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $31.60 | 2021-2022 | |
| Novo Nordisk INC | $30.04 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $27.32 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.00 | 2022 | |
| Amgen INC. | $20.14 | 2021 | |
| Abbott Laboratories | $14.39 | 2022 | |
| Glaxosmithkline, LLC. | $13.62 | 2023 | Bexsero, Menveo, Pediarix |
| Sobi, INC | $13.44 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Peng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.